Lazier CB - Search Results

1

5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.

Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB. Thomas LN, et al. Among authors: lazier cb. J Urol. 2003 Nov;170(5):2019-25. doi: 10.1097/01.ju.0000091804.20183.81. J Urol. 2003. PMID: 14532845

2

Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.

Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS, Too CK. Thomas LN, et al. Among authors: lazier cb. J Urol. 2008 Jan;179(1):147-51. doi: 10.1016/j.juro.2007.08.155. Epub 2007 Nov 13. J Urol. 2008. PMID: 17997435

3

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.

Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Thomas LN, et al. Among authors: lazier cb. Eur Urol. 2008 Feb;53(2):244-52. doi: 10.1016/j.eururo.2007.10.052. Epub 2007 Nov 5. Eur Urol. 2008. PMID: 18006217 Review.

4

Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.

Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Wright AS, et al. Among authors: lazier cb. Endocrinology. 1999 Oct;140(10):4509-15. doi: 10.1210/endo.140.10.7039. Endocrinology. 1999. PMID: 10499505

5

The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer.

Rittmaster RS, Thomas LN, Wright AS, Murray SK, Carlson K, Douglas RC, Yung J, Messieh M, Bell D, Lazier CB. Rittmaster RS, et al. Among authors: lazier cb. J Urol. 1999 Dec;162(6):2165-9. doi: 10.1016/S0022-5347(05)68153-0. J Urol. 1999. PMID: 10569613

6

Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5.

Thomas LN, Wright AS, Lazier CB, Cohen P, Rittmaster RS. Thomas LN, et al. Among authors: lazier cb. Prostate. 2000 Feb 15;42(3):203-10. doi: 10.1002/(sici)1097-0045(20000215)42:3<203::aid-pros6>3.0.co;2-y. Prostate. 2000. PMID: 10639191 Clinical Trial.

7

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Lazier CB, et al. Prostate. 2004 Feb 1;58(2):130-44. doi: 10.1002/pros.10340. Prostate. 2004. PMID: 14716738

8

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Andriole GL, et al. Among authors: lazier cb. J Urol. 2004 Sep;172(3):915-9. doi: 10.1097/01.ju.0000136430.37245.b9. J Urol. 2004. PMID: 15310997 Clinical Trial.

9

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.

Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS. Thomas LN, et al. Among authors: lazier cb. Prostate. 2005 May 15;63(3):231-9. doi: 10.1002/pros.20188. Prostate. 2005. PMID: 15538746

10

Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats.

Thomas LN, Cohen P, Douglas RC, Lazier C, Rittmaster RS. Thomas LN, et al. Prostate. 1998 Jun 1;35(4):273-8. doi: 10.1002/(sici)1097-0045(19980601)35:4<273::aid-pros6>3.0.co;2-h. Prostate. 1998. PMID: 9609550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters